1. Home
  2. IOVA vs NCMI Comparison

IOVA vs NCMI Comparison

Compare IOVA & NCMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • NCMI
  • Stock Information
  • Founded
  • IOVA 2007
  • NCMI 2005
  • Country
  • IOVA United States
  • NCMI United States
  • Employees
  • IOVA N/A
  • NCMI N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • NCMI Advertising
  • Sector
  • IOVA Health Care
  • NCMI Consumer Discretionary
  • Exchange
  • IOVA Nasdaq
  • NCMI Nasdaq
  • Market Cap
  • IOVA 771.4M
  • NCMI 476.2M
  • IPO Year
  • IOVA N/A
  • NCMI 2007
  • Fundamental
  • Price
  • IOVA $1.74
  • NCMI $4.79
  • Analyst Decision
  • IOVA Buy
  • NCMI Strong Buy
  • Analyst Count
  • IOVA 10
  • NCMI 5
  • Target Price
  • IOVA $12.22
  • NCMI $7.40
  • AVG Volume (30 Days)
  • IOVA 11.7M
  • NCMI 603.6K
  • Earning Date
  • IOVA 08-07-2025
  • NCMI 08-04-2025
  • Dividend Yield
  • IOVA N/A
  • NCMI 2.51%
  • EPS Growth
  • IOVA N/A
  • NCMI N/A
  • EPS
  • IOVA N/A
  • NCMI N/A
  • Revenue
  • IOVA $212,679,000.00
  • NCMI $238,300,000.00
  • Revenue This Year
  • IOVA $86.62
  • NCMI $10.10
  • Revenue Next Year
  • IOVA $69.95
  • NCMI $11.66
  • P/E Ratio
  • IOVA N/A
  • NCMI N/A
  • Revenue Growth
  • IOVA 11070.12
  • NCMI 42.10
  • 52 Week Low
  • IOVA $1.64
  • NCMI $4.12
  • 52 Week High
  • IOVA $12.51
  • NCMI $7.60
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 38.67
  • NCMI 38.30
  • Support Level
  • IOVA $1.67
  • NCMI $4.65
  • Resistance Level
  • IOVA $1.82
  • NCMI $4.99
  • Average True Range (ATR)
  • IOVA 0.12
  • NCMI 0.17
  • MACD
  • IOVA -0.00
  • NCMI -0.04
  • Stochastic Oscillator
  • IOVA 13.85
  • NCMI 18.42

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

Share on Social Networks: